Study Phase 3

A Phase 3 Open-label Study to Assess the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Ustekinumab in the Treatment of Moderate to Severe Chronic Plaque Psoriasis in Pediatric Subjects Greater Than or Equal to 6 to Less Than 12 Years of Age

  • PDF icon for CSR Summary CSR Summary Not Available
  • Globe symbol for NCT Number NCT02698475
  • Notebook for Primary Citation Primary Citation Trial has yet to be published
  • Spreadsheet for Data Specification Data Specification Not Available

Trial Information

Generic NameUstekinumabProduct NameSTELARA®Therapeutic AreaImmune System DiseasesEnrollment44% FemaleN/A% WhiteN/A
Product ClassAntipsoriaticsSponsor Protocol NumberCNTO1275PSO3013Data PartnerJohnson & JohnsonCondition StudiedPsoriasisMean/Median Age (Years)8.90

Supporting Documentation

  • Collected Datasets Available
  • Protocol with Amendments Available
  • Statistical Analysis Plan Available
  • Clinical Study Report Available

Approved Data Requests Associated with this Trial

Disclaimer

Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.